X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Guest Post: Using the patient voice to go boldly

By Guest Contributor  |    May 30, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

IP Explained: How Hatch-Waxman successfully balances affordability and innovation

By Tom Wilbur  |    May 22, 2019
For three decades, The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, has fostered innovation, spurred competition and helped the United...   Read More

Guest post: Hearing from patients on Rare Disease Day

By Guest Contributor  |    February 28, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation

By Richard Moscicki, M.D.  |    February 28, 2019
Today is Rare Disease Day, an annual reminder of the incredible community of patients living with a rare disease. In the U.S., rare diseases are classified as conditions that affect fewer than...   Read More

Why state drug importation pilot programs don’t work

By Nick McGee  |    February 8, 2019
Across the country, some states are recirculating failed proposals that would establish state-run prescription medicine importation schemes. Such proposals would allow medicines from foreign...   Read More

Putting 2018 medicine approvals in context

By Andrew Powaleny  |    January 23, 2019
Last year, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved a record number of novel new medicines with 59 new molecular entities (NMEs). While...   Read More

FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies

By Richard Moscicki, M.D.  |    October 16, 2018
The U.S Food and Drug Administration (FDA) plays a critical role in protecting and promoting the health of all Americans. Every day, the FDA does important work to ensure the safety, efficacy and...   Read More

Balancing innovation and competition in the biologics marketplace

By David Korn  |    October 11, 2018
Last month, I presented at the U.S. Food and Drug Administration’s (FDA) Public Hearing on Facilitating Competition and Innovation in the Biological Products Marketplace. The hearing was part of...   Read More

New analysis shows that more medicines worldwide are available to U.S. patients

By Kevin Haninger  |    June 5, 2018
In the past year, we have seen revolutionary new treatments become available to patients in the United States for cancer and other debilitating diseases. A new analysis puts in perspective the...   Read More

Spending on medicines grew less than one percent in 2017

By Holly Campbell  |    April 19, 2018
Last year, a record number of new treatments and cures that are transforming care for patients fighting debilitating diseases like cancer, hepatitis C, high cholesterol and more were approved by...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates